BioWorld

March 7, 2007

Speedel, Novartis Gain FDA Approval Of Hypertension Drug

The FDA approved a new drug for high blood pressure, Tekturna (aliskiren), a first-in-class product partnered between Speedel Group and Novartis AG. (BioWorld Today) Read More

InterMune Stopping Phase III IPF Program With Actimmune

Microbicide Research Advances Despite Recent Clinical Setbacks

BioCryst Getting $14M Up Front From Japanese Peramivir Partner

PainCeptor Brings In C$24.4M To Advance Pain Programs

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...